RVTY — REVVITY, INC.

NYSE · Unknown · Unknown · CIK 31791 ·
Last close
$96.83
Market Cap
$10.80B
52W High
$103.00
52W Low
$81.22
ADV30
1,382,577
Next earnings
2026-07-27
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026
Dec 2025 772,056,000 421,659,000 111,749,000 98,364,000 12,168,411,000 919,860,000 4,918,051,000
Sep 2025 698,949,000 374,604,000 81,896,000 46,652,000 12,138,952,000 931,386,000 4,763,056,000
Jun 2025 720,284,000 392,556,000 89,065,000 53,948,000 12,362,789,000 991,849,000 4,806,621,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$588,956,000
Investing CF
$-73,603,000
Financing CF
$-857,523,000
CapEx
$-73,522,000
Dividends Paid
$-32,800,000
Buybacks
$-820,815,000
EPS Diluted TTM
$2.09
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$6,054,314,000
Inventory
$379,497,000
Receivables
$744,671,000
ST Investments
EBIT TTM
$285,116,000
Pretax Income TTM
$215,895,000
Interest Exp TTM
$69,221,000
Analysts
14

Yahoo Snapshot (yfinance, live)

Total Revenue
$2,902,406,912
EBITDA
$855,235,008
Free Cash Flow
$508,969,248
Enterprise Value
$13,305,578,496
Total Cash
$860,320,000
Total Debt
$3,350,179,072
Shares Out
111,559,773
Trailing EPS
$2.08
Book Value
$64.20
ROE
3.2%
ROA
2.3%
Div Yield
0.29%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 2,856,051,000 356,635,000 241,201,000 12,168,411,000 4,918,051,000 582,933,000
Dec 2024 2,755,026,000 346,741,000 270,385,000 12,392,478,000 4,725,604,000 628,299,000
Dec 2023 2,750,571,000 300,562,000 693,094,000 13,564,665,000 5,691,926,000 91,272,000
Dec 2022 3,311,822,000 742,699,000 569,179,000 14,129,855,000 6,746,979,000 679,810,000

TTM Snapshot

Revenues TTM
$2,927,907,000
NetIncome TTM
$316,949,000
OpCashFlow TTM
$0
Assets (Latest)
$12,392,478,000
Forward EPS
$5.81

News headlines (Yahoo Finance, 1h cache)

Revvity Stock: Analyst Estimates & Ratings
2026-05-22 14:00 · Yahoo
Revvity's (NYSE:RVTY) Conservative Accounting Might Explain Soft Earnings
2026-05-20 10:21 · Yahoo
The Top 5 Analyst Questions From Revvity’s Q1 Earnings Call
2026-05-15 11:16 · Yahoo
RVTY Expands Endocrine Diagnostics With FDA-Cleared Testosterone Assay
2026-05-14 15:59 · Yahoo
Revvity Receives FDA Clearance for Total Testosterone Assay Enabling Comprehensive Automated Testosterone Testing Solution
2026-05-13 12:00 · Yahoo
3 Cash-Producing Stocks That Concern Us
2026-05-12 14:36 · Yahoo
Is Revvity’s (RVTY) China Exit and EPS Reset Quietly Rewriting Its Portfolio Strategy?
2026-05-07 16:15 · Yahoo
Revvity, Inc. Q1 2026 Earnings Call Summary
2026-05-05 16:52 · Yahoo
Revvity (RVTY) Q1 2026 Earnings Transcript
2026-05-05 15:44 · Yahoo
RVTY Q1 Earnings Beat Estimates on Organic Growth & Strong Execution
2026-05-05 14:40 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.